Effects of Novel Isoform-Selective Phosphoinositide 3-Kinase Inhibitors on Natural Killer Cell Function

Sung Su Yea1,2,*, Lomon So1, Sharmila Mallya1, Jongdae Lee1, Kamalakannan Rajasekaran3, Subramaniam Malarkannan3, David A. Fruman1*

1 Department of Molecular Biology & Biochemistry, and Institute for Immunology, University of California Irvine, Irvine, California, United States of America, 2 Department of Biochemistry, College of Medicine, Inje University, Busan, Korea, 3 Laboratory of Molecular Immunology and Immunotherapy, Blood Research Institute, Milwaukee, Wisconsin, United States of America

Abstract

Phosphoinositide 3-kinases (PI3Ks) are promising targets for therapeutic development in cancer. The class I PI3K isoform p110α has received considerable attention in oncology because the gene encoding p110α (PIK3CA) is frequently mutated in human cancer. However, little is known about the function of p110α in lymphocyte populations that modulate tumorigenesis. We used recently developed investigational inhibitors to compare the function of p110α and other isoforms in natural killer (NK) cells, a key cell type for immunosurveillance and tumor immunotherapy. Inhibitors of all class I isoforms (pan-PI3K) significantly impaired NK cell-mediated cytotoxicity and antibody-dependent cellular cytotoxicity against tumor cells, whereas p110α-selective inhibitors had no effect. In NK cells stimulated through NKG2D, p110α inhibition modestly reduced PI3K signaling output as measured by AKT phosphorylation. Production of IFN-γ and NK cell-derived chemokines was blocked by a pan-PI3K inhibitor and partially reduced by a p110α inhibitor, with lesser effects of p110α inhibitors. Oral administration of mice with MLN1117, a p110α inhibitor in oncology clinical trials, had negligible effects on NK subset maturation or terminal subset commitment. Collectively, these results support the targeting of PIK3CA mutant tumors with selective p110α inhibitors to preserve NK cell function.

Introduction

The immune system plays both negative and positive roles in cancer development [1]. Lymphocyte subsets including NK cells and cytotoxic T lymphocytes can recognize and kill tumor cells. Conversely, inflammatory cells can promote tumor initiation and development, and regulatory T cells maintain an immunosuppressive milieu in tumors and draining lymph nodes. Drugs developed against molecular targets in tumors have the potential to modify the function of all of these leukocyte populations, enhancing or interfering with immunotherapeutic strategies [2,3]. Therefore, it is critical to define the effects of emerging cancer therapies on immune function.

A major target of experimental cancer drugs is the PI3K signaling pathway, which is aberrantly activated in most human tumors [4–6]. In recent years, candidate agents with good pharmacological properties and acceptable toxicity in animals have entered clinical trials for oncology. There are two main classes of PI3K inhibitor. The first class includes compounds selective for individual class I PI3K isoforms (p110α, p110β, p110γ or p110δ). The other class encompasses “pan-PI3K” inhibitors with similar potency against all class I PI3K enzymes. Isoform-selective inhibitors targeting either p110α or p110δ have received particular attention in oncology [4–6]. The rationale for p110α-selective inhibitors is that activating mutations in PIK3CA, encoding p110α, are common in epithelial tumors [7,8]. Preclinical studies indicate that p110α-selective compounds are equally effective as pan-PI3K inhibitors at reducing growth of PIK3CA mutant tumor cells [9–11]. The main factor driving interest in p110α has been the dramatic and unpredicted success of p110δ inhibitors in early clinical trials of B cell malignancies [4,12]. Compounds with activity against p110β or p110γ might also suppress growth of certain cancers [13,14]. Recent advances in medicinal chemistry have produced refined chemical tools to probe the function of individual PI3Ks in different cell types [4,6]. In this study we compared pan-PI3K and isoform-selective inhibitors in assays of NK cell function. NK cells are important for host defense to viral infections, killing virally-infected cells directly and producing cytokines that influence other cells of innate and adaptive immunity [15,16]. NK cells are also critical for tumor immunosurveillance and can be used in adoptive immunotherapy [17]. NK cells display natural cell-mediated cytotoxicity (CMC) against cancer cells through the detection of stress ligands (also known as “induced self”), mediated by NKG2D.
and other activating receptors, or through recognition of “missing self” when tumor cells have low surface expression of MHC class I molecules. In addition, NK cells mediate antibody-dependent cellular cytotoxicity (ADCC) through Fcγreceptor-dependent recognition of antibody-coated targets. There is evidence that ADCC mediated by NK cells and monocytes plays a major role in destruction of tumor cells in humans treated with therapeutic antibodies such as cetuximab, trastuzumab and rituximab [18,19]. Ideally, targeted anti-cancer agents should not interfere with the ability of NK cells to produce cytokines or kill tumor cells. However, various NK receptors activate PI3K and broad spectrum PI3K inhibitors strongly suppress NK cell function [20–24]. Until recently it was not possible to test the role of p110α in NK cells; mutations in the mouse p110α gene are embryonic lethal [25] and selective inhibitors were not available. Using newly developed compounds with high selectivity for p110α [11], we tested the hypothesis that p110α inhibitors have lesser effects than pan-PI3K inhibitors on crucial functions of NK cells. The results support this prediction and show that multiple PI3K isoforms have overlapping and largely redundant roles.

Results

Pan-PI3K inhibitors strongly suppress NK CMC

Several studies have shown that PI3K inhibitors suppress NK cell-mediated cytotoxicity towards tumor cell lines. Early reports employed non-selective compounds such aswortmannin and LY294002 that also inhibit other cellular enzymes at the concentrations used [20,24]. Additional evidence that PI3K is required for NK CMC has emerged from genetic and pharmacological inhibition of the PI3K isoforms p110α or p110β [24,26–30]. To confirm the PI3K-dependence of NK cell functions under our experimental conditions, we used the selective pan-class I inhibitors ZSTK474 [31,32] and GDC-0941 [33–35]. As shown in Table 1, both compounds inhibit all four class I PI3K enzymes in the low to mid-nanomolar range in vitro; in cellular assays these compounds block PI3K signaling selectively when used at 0.1–1 μM. For cytotoxicity assays, we first used purified murine NK cells (Fig. S1) expanded and activated for one week with recombinant human IL-2. These cells effectively lyzed lymphoma target cells lacking MHC class I (RMA-S) or cells expressing the H60 stress ligand for NKG2D (EL4H60), compared to their respective control cell lines RMA and EL4 (Fig. S2A). ZSTK474 strongly suppressed CMC against both target cells over a wide range of E:T ratios (Fig. S2A). The effect of ZSTK474 was dose-dependent, with maximal efficacy at 1 μM (Fig. S2B). GDC-0941 also suppressed CMC towards RMA-S and EL4H60 cells (Fig. 1B, C). Both ZSTK474 and GDC-0941 blocked NK cell killing of YAC-1 cells, a commonly used lymphoma target cell line naturally expressing stress ligands (Fig. 1B, C). These experiments establish conditions in which CMC is absolutely dependent on class I PI3K activity.

Isoform-selective PI3K inhibitors have minimal effect on NK cytotoxicity

Murine NK cells express each of the four class I PI3K isoforms as detected by immunoblot (Fig. 1A). The expression levels in NK cells were similar to T lymphocytes, both of which expressed much less p110α and p110β than solid tumor cell lines SKOV3 and U87MG (Fig. 1A). Expression of p110α in NK cells and T cells was slightly lower than in B cells (Fig. 1A), a cell type in which p110α inhibition significantly reduces PI3K signaling output following antigen receptor crosslinking [11]. To define the contributions of individual PI3K isoforms to the overall CMC response in NK cells, we employed a panel of inhibitors we described recently in a study of T and B lymphocytes [11]. MLN1117 (formerly INK1117) and A66 are structurally distinct compounds selective for p110α in vitro (Table 1) and are selective for p110α in cells when used at 1 μM [11,36]. TGX-221 is a well-characterized p110β-selective inhibitor when used at 500 nM (Table 1) [37,30]. We also tested the compound INK1316, which inhibits both p110α and p110β in vitro (Table 1) [11]. To inhibit p110α we used IC57114, a highly selective compound (Table 1) that has been widely used in lymphocyte studies [39,40] and impairs NK cell chemotaxis at 1 μM [28]. At concentrations higher than 1 μM, IC57114 has off-target effects [40]. To inhibit p110γ we used the compound AS252424 (Table 1) at a concentration (1 μM) used in previous studies of NK cells [24,28]. None of the compounds were directly toxic to either the NK cells or the target cells (Fig. S3).

Selective inhibition of p110α, p110β or p110γ did not significantly reduce NK cell-mediated killing of RMA-S, EL4H60 or YAC-1 cells (Fig. 1B, C). Raising the concentration of MLN1117 to 2 μM still did not inhibit killing of YAC-1 cells (Fig. 1D). The dual p110α/p110β inhibitor INK1316 likewise did not significantly reduce CMC towards RMA-S and YAC-1 cells (Fig. 1C). The p110α inhibitor IC57114 modestly reduced killing of RMA-S and YAC-1 cells at some but not all E:T ratios (Fig. 1B), but the magnitude of the inhibition was much less than achieved with GDC-0941.

As a model of ADCC, we cultured mouse NK cells together with a human CD4+ T cell lymphoma line (CCRFP-CEM) in the presence of mouse anti-human CD4 monoclonal antibody. Similar to the CMC results, ADCC was strongly reduced by the pan-PI3K inhibitor GDC-0941 but not by isoform-selective inhibitors targeting p110α, p110β, p110γ or p110δ (Fig. 2). Together these experiments establish that individual class I PI3K isoforms have overlapping, redundant roles in NK cell-mediated killing of target cells via recognition of missing self (RMA-S), stress ligands (YAC-1 and EL4-H60) or antibody (CCRFP-CEM plus anti-CD4).

To extend these findings to human NK cells, we assessed killing of K562 target cells by primary human NK cells from three different donors. As in mouse NK cells, the pan-PI3K inhibitors GDC-0941 and ZSTK474 significantly suppressed CMC at all E:T ratios (Fig. 3A) confirming the PI3K-dependence of the response. In this system, we observed again that isoform-selective inhibitors had minimal effect. Similar results were obtained using the human NK cell lines NKI (Fig. 3B) and NK92 (Fig. 3C).

Isoform-selective PI3K inhibitors partially reduce AKT phosphorylation in stimulated NK cells

To determine the impact of different PI3K inhibitors on a proximal signaling event, we measured phosphorylation of AKT. Membrane recruitment, phosphorylation and activation of AKT is a critical PI3K-dependent signal in many cell types. In accord, a selective AKT inhibitor strongly suppressed NK cell cytotoxicity towards YAC-1 cells (Fig. 4A). In NK cells stimulated with anti-NKG2D, AKT phosphorylation increased within 5 minutes and reached a maximum around 20 minutes (Fig. 4B). Pretreatment with GDC-0941 abolished the increase in pAKT (Fig. 4C), showing that the measured phosphorylation is dependent on class I PI3Ks. Selective inhibitors of p110α, p110β or p110δ partially reduced pAKT (Fig. 4C). These results suggest that each isoform contributes to PI3K signaling output following NK stimulation through NKG2D.
Redundant roles of different PI3K isoforms in NK cell production of cytokines and chemokines

NK cells produce many different cytokines and chemokines upon engagement of activating receptors [16]. These secreted factors influence several cell types of the innate and adaptive immune systems. IFN-γ secretion by NK cells is particularly important for controlling replication of intracellular pathogens and promoting T helper type I responses [41]. We measured IFN-γ production following stimulation with plate-bound antibodies to activating receptors (NKG2D or NK1.1), after a 15 min pretreatment with drugs. In cells stimulated with anti-NKG2D for 18 hours, GDC-0941 but not MLN1117 suppressed production of IFN-γ protein measured by ELISA (Fig. 5A, left). Anti-NKG2D strongly induced IFN-γ mRNA after 6 hours, and this response was nearly abolished by GDC-0941 (Fig. 5A, right). MLN1117 and other isoform-selective inhibitors did not significantly reduce IFN-γ mRNA at this time point, though there was a trend to reduced mRNA in cells treated with TGX-221, INK1316 or IC87114 (Fig. 5A, right). To determine the percentage of NK cell...
cells producing IFN-γ, we performed intracellular cytokine staining. 18 hours after stimulation with anti-NKG2D or anti-NK1.1, approximately 10–15% of NK1.1+ cells expressed IFN-γ at a level detectable in this assay (Fig. 5B, C and Fig. S5). GDC-0941 reduced the percentage of IFN-γ+ NK cells to background levels at all drug concentrations tested (Fig. 5B, C). The two p110α inhibitors modestly reduced the percentage of IFN-γ+ NK cells in response to anti-NKG2D, but this was not statistically significant when anti-NK1.1 was used (Fig. 5B, C). Isoform-selective inhibitors of p110β or p110δ also had a significant effect on the response to anti-NKG2D but not anti-NK1.1, yet none of these compounds approached the complete inhibition achieved by GDC-0941 (Fig. 5B, C).

Next we measured production of a large panel of cytokines and chemokines using a bead based bioplex assay. We stimulated cells from four different mice with anti-NKG2D either in the absence or presence of exogenous IL-12 and IL-18, which enhance cytokine production by NK cells (Fig. 5D). The amounts of classical NK-derived cytokines (IFN-γ, GM-CSF) and chemokines (MIP-1α, MIP-1β, RANTES; also known as CCL3, CCL4, CCL5) increased significantly in supernatants from anti-NKG2D-stimulated cells compared to unstimulated control (Fig. 6A, B). In the presence of IL-12 and IL-18, NK cells produced 70–200 fold more IFN-γ and chemokines but only slightly more GM-CSF (compare Fig. 6B to 6A). The pan-PI3K inhibitor GDC-0941 strongly and significantly reduced production of each cytokine/chemokine under both stimulation conditions (Fig. 6A, B). The p110δ-selective inhibitor IC87114 caused an intermediate reduction of these cytokines and chemokines, which was statistically significant except for GM-CSF produced in the presence of IL-12 and IL-18 (Fig. 6A, B). A key observation was that in NK cells treated with the p110α inhibitors or p110β inhibitor, cytokine production was reduced to a lesser degree than in cells treated with IC87114. These reductions were not statistically significant in NK cells stimulated in the presence of IL-12 and IL-18.

Table 1. Selectivity and effective concentrations of inhibitors used in this study (reported in the following references: 11, 26, 31, 34, 38, 40).

| Inhibitor     | Selectivity | Effective Concentrations                 |
|---------------|-------------|------------------------------------------|
| MLN1117       | p110α       | In vitro IC50: 15 nM (p110α), >1 μM (other isoforms) Cellular Assays: selective for p110α at 1 μM |
| A66           | p110α       | IC50: 32 nM (p110α), >1 μM (other isoforms) Cellular Assays: 1 μM |
| TGX-221       | p110β       | IC50: 5 nM (p110β), 100 nM (p110δ), >5 μM (other isoforms) Cellular Assays: 500 nM |
| INK1316       | Dual p110α/β| IC50: 10 nM (p110α), 8 nM (p110β), >750 nM (other isoforms) Cellular Assays: 1 μM |
| AS252424      | p110γ       | IC50: 30 nM (p110γ), >1 μM (other isoforms) Cellular Assays: 1 μM |
| IC87114       | p110δ       | IC50: 70 nM (p110δ), >1 μM (other isoforms) Cellular Assays: 1 μM |
| GDC-0941      | Pan-PI3K    | IC50: 3 nM (p110α), 33 nM (p110β), 75 nM (p110γ), 3 nM (p110δ) Cellular Assays: 250 nM–1 μM |
| ZSTK474       | Pan-PI3K    | IC50: 16 nM (p110α), 44 nM (p110β), 49 nM (p110γ), 4.6 nM (p110δ) Cellular Assays: 250 nM–1 μM |

Figure 2. A pan-PI3K inhibitor, but not isoform-selective inhibitors, suppresses ADCC. CCRF-CEM, human acute T lymphocytic leukemia cell line was labeled with calcine AM, incubated with mouse anti-human CD4 mAb, and then co-cultured with NK cells at 10:1 E:T ratio in the presence of indicated inhibitors for 2 h. Culture supernatants were collected and calcine fluorescence was measured and analyzed as in Figure 1. The values are presented as the means ± SEM from three independent experiments. *p<0.05 and **p<0.01, as determined by the unpaired Student’s t test using Sigma Plot 10 software and as compared to the vehicle control group.
Several other cytokines and chemokines were produced at lower levels than the classical NK cell products presented in Figure 6. Figure 7 shows results for products present above 1 ng/ml in supernatants of stimulated cells. We chose this cut-off based on the sensitivity of the detection assay (see figure legend). IL-9 was produced constitutively (5 ng/ml) and this was not strongly increased by stimulation with anti-NKG2D or IL-12/IL-18 (Fig. 7A, B). PI3K inhibitors including GDC-0941 did not reduce IL-9 production, indicating that the PI3K inhibitors were not generally toxic to NK cells or the secretory pathway. In NK cells cultured in the absence of IL-12/IL-18, anti-NKG2D increased production of IL-1β, IL-12 (p70), IL-13, and MCP-1 and all were reduced by GDC-0941 and the dual p110α/β inhibitor (Fig. 7A). IC87114 significantly reduced production of IL-1β, IL-13, and MCP-1 but not IL-12 (p70). The p110α inhibitor and p110β inhibitor had variable effects that were significant for some products. NK cells cultured in IL-12 and IL-18 produced a similar set of cytokines (IL-1β, IL-13, and MCP-1), but at higher amounts particularly for IL-13 (Fig. 7B). Again, GDC-0941 and INK1316 significantly reduced production of IL-1β, IL-13, and MCP-1. Under these conditions, inhibitors of individual PI3K isoforms caused a trend towards lower cytokine/chemokine production but these were not significant.

Considered together, the bioplex data combined with intracellular cytokine staining suggest that p110α, p110β and p110δ contribute to the overall PI3K signal driving cytokine production, with p110δ mediating the greatest quantitative input in some cases. However, each of the isoform-selective inhibitors has a lesser impact on cytokine production compared to pan-PI3K inhibition in these in vitro studies. This pattern correlates closely with the

Figure 3. Isoform-selective inhibitors have little effect on cytotoxicity of human NK cells. (A) K562 cells were labeled with 51Cr and co-cultured with human primary NK cells at the indicated E:T ratios in the presence of 1 μM indicated inhibitors (TGX-221, GDC-0941, and ZSTK474 were 0.5 μM) for 2 h. Specific 51Cr release was measured as described [46]. (B) K562 cells were labeled with calcein AM and co-cultured with human NK cells at 10:1 E:T ratio in the presence of 1 μM indicated inhibitors (TGX-221 was 0.5 μM) for 2 h. Culture supernatants were collected and calcein fluorescence was measured and analyzed as in Figure 1. The data are expressed as the means ± SEM of three independent experiments. An asterisk denotes any response that is significantly different from the vehicle control group as determined by the unpaired Student’s t test using Sigma Plot 10 software (*, p<0.05, **, p<0.01, and ***, p<0.001).

doi:10.1371/journal.pone.0099486.g003

Effect of Novel PI3K Inhibitors on NK Cells
results from pAKT measurements in Figure 4, and with cytotoxicity results in Figure 1.

Treatment with PI3K inhibitors in vivo has minimal effect on NK cell maturation or survival

Previously we showed that mouse B cell subset frequencies are altered by in vivo dosing with the pan-PI3K inhibitor GDC-0941 but not by the p110α inhibitor MLN1117 [11]. To test the effect of these drugs on NK cell frequencies and maturation state, mice were given daily oral doses of GDC-0941 or MLN1117 for one week, or treated with vehicle control. We used doses and formulations shown previously to suppress growth of PIK3CA mutant tumors in xenograft models [10,35]. As we reported [11], GDC-0941 but not MLN1117 significantly reduced the percentage of B cells with a marginal zone phenotype (CD21hiCD23lo) (Fig. 8A). Neither compound altered the percentages of T cells and B cells or the fractions of CD4 and CD8 T cells in spleen, or the percentages of NK cells in spleen and bone marrow (Fig. 8B, C, D).

In mice treated with GDC-0941 or MLN1117 for one week, there was no significant change in the percentages of NK cells representing different maturation stages based on staining for CD27 and CD11b (Fig. 8E). Staining for various subsets based on Ly49 and NKG family members and CD122 did not reveal major changes in mice treated with PI3K inhibitors (Fig. 8F, G). GDC-0941 caused a small but significant decrease in the percentage of Ly49A+ and Ly49C/I+ cells, and MLN1117 also decreased the Ly49C/I+ compartment. Overall, these data indicate that class I PI3K inhibition in mice for one week does not cause general lymphopenia or reduce NK cell numbers, nor does it strongly dysregulate NK homeostasis. Further experiments are necessary to evaluate the effects of different PI3K inhibitors on CMC, ADCC and cytokine production in vivo.

Discussion

p110α is an important cancer drug target but is expressed ubiquitously [4,25,42]. Therefore, it is essential to define the function of this PI3K isoform in normal tissues and cells, particularly those that modulate tumor growth and survival. Here we used new chemical tools to probe the function of p110α in NK cells. We compared the effects of p110α inhibitors to the impact of other isoform-selective inhibitors, and to compounds with a pan-PI3K profile. The results show that pan-PI3K inhibition strongly suppresses CMC, ADCC and cytokine production by NK cells, whereas inhibition of p110α has much lesser impact on NK cell function in vitro. We used two different p110α inhibitors, MLN1117 and A66, at concentrations that suppress signaling and growth of PIK3CA mutant cancer cells [10,11,36]. Both compounds seemed to reduce CMC and release of certain cytokines, but in most cases these effects did not reach statistical significance. These findings suggest a potential advantage of p110α-selective inhibitors in clinical development for oncology for further study: relative to pan-PI3K inhibition, selective blockade of p110α should leave key NK cell functions intact such as ADCC. This property might prove particularly important in patients...
treated with PI3K inhibitors together with immunotherapeutic antibodies like trastuzumab.

Treatment of mice for one week with either GDC-0941 or MLN1117 had negligible effects on NK cell numbers or subset frequencies. These data fit with in vitro experiments showing lack of direct cytotoxic effects of PI3K inhibitors on NK cells (Fig. S2). It is possible that longer treatments in vivo would affect NK cell maturation or survival. It would be interesting to compare the effects of pan-PI3K and isoform-selective inhibitors on NK cell functions in vivo, such as lysis of tumor cells. We tried several models of NK-mediated rejection, including co-injection of differentially labeled RMA and RMA-S cells into the peritoneal cavity of syngeneic mice. Although we observed selective clearance of RMA-S cells, characteristic of an NK anti-tumor effect, we found that GDC-0941 treatment had no consistent effect compared to vehicle control (data not shown). A literature search did not identify any previous publications demonstrating that a chemical PI3K inhibitor impairs NK cell function in vivo. A likely explanation is that currently available pan-PI3K inhibitors are not tolerated at doses that completely inhibit PI3K activity, or that the pharmacokinetics are insufficient to maintain complete suppression of all PI3K isoforms in NK cells over the time course of tumor rejection models. The doses we used of GDC-0941 were sufficient to reduce marginal zone B cell populations, indicating inhibition of p110<sub>c</sub> and p110<sub>d</sub>, but might not have inhibited other isoforms to the same extent. Further work is required to establish a system in which NK cell function is reduced by a pan-PI3K inhibitor, in order to compare with isoform-selective compounds.

Our data add to the knowledge base of p110<sub>c</sub> and p110<sub>d</sub> function in murine NK cells. The role of these isoforms has been investigated previously using mice with null or inactivating mutations in the Pik3cg and Pik3cd genes encoding these catalytic subunits [24,27–30]. Genetic inactivation of p110<sub>c</sub> impairs NK cell maturation, and NK cells lacking this isoform display various defects in response to chemokines and activatory receptors [24,28,29]. However, a previous study reported that acute inhibition of p110<sub>c</sub> with AS252424 did not affect CMC or IFN-γ production by wild-type NK cells [24]. Our data confirm that AS252424 does not impede CMC or production of numerous cytokines by NK cells. It is possible that impaired function of NK cells with genetic p110<sub>c</sub> deficiency results from development defects.

In contrast, there are consistent data that p110<sub>d</sub> has a measurable contribution to NK cell biology. Earlier studies using...
p110\(\delta\) kinase-dead knockin mice demonstrated a reduced NK cellularity and a selective impairment in the terminal maturation of Ly49C and Ly49I NK subsets and an alteration in CD27 and CD11b-based NK subsets [27]. Several studies have also shown reduced CMC and cytokine production by NK cells lacking p110\(\delta\) function [24,27,29], and others showed impaired chemotaxis and CMC using either genetic inactivation or treatment with IC87114 [28,30]. Consistent with these reports, we found that IC87114 (1 \(\mu\)M) reduced mouse NK CMC towards RMA-S and YAC-1 cells and diminished production of IFN-\(\gamma\) and some other cytokines. However, IC87114 did not significantly reduce human NK CMC towards K562 cells. Whether p110\(\delta\) inhibitors currently in clinical trials interfere with NK cell function in humans will be important to address. Thus far, the clinical data reported at conferences indicate favorable responses to the combination of CAL-101 and rituximab, suggesting that p110\(\delta\) inhibition does not greatly interfere with the therapeutic mechanism of the antibody [4]. However, inhibiting p110\(\delta\) might affect NK cell extravasation and tumor infiltration efficiency [28]. p110\(\delta\) inhibitors may also impair the function of cytotoxic T lymphocytes [43].

The anti-cancer activity of compounds targeting PI3K enzymes will depend not only on direct effects on tumor cells but also on indirect modulation of immune cells. The immune effects of PI3K inhibitors will also influence the efficacy of immunotherapies used in combination. The data presented here suggest that selective p110\(\alpha\) inhibition will preserve the function of NK cells, an important cell type in tumor immunosurveillance and immunotherapy.

Figure 6. Selective p110\(\alpha\) inhibitors have lesser effect on cytokine/chemokine production in NK cells. NK cells from C57BL/6 mice were purified from spleen and expanded for 7–8 days in IL-2. (A–B) The NK cells were pre-treated with vehicle (0.1% DMSO or 0.1% ethanol) or 1 \(\mu\)M indicated inhibitors (TGX-221 was 0.5 \(\mu\)M) for 15 min, followed by stimulation with plate-bound anti-NKG2D mAb in the absence (A) or presence (B) of IL-12 and IL-18 for 18 h. The supernatants were collected and analyzed by Multiplex assay. The data are expressed as the means ± SEM of four independent NK cell preparations that were stimulated and analyzed concurrently. Statistical analysis was performed with one-way ANOVA using Prism 6 (GraphPad Software, Inc.) to compare the differences between vehicle and each inhibitor-treated group. *, \(p<0.05\), **, \(p<0.01\), and ***, \(p<0.001\).

doi:10.1371/journal.pone.0099486.g006

erceptors [13,44,45]. Inhibitors of p110\(\beta\) or dual p110\(\alpha/\beta\) inhibitors have been considered as possible options in human tumors driven by PTEN loss [4]. Our data indicate that while p110\(\beta\) protein expression is barely detectable, inhibiting p110\(\beta\) has a modest effect on NK cells functions similar to inhibiting p110\(\alpha\). The dual p110\(\alpha/\beta\) inhibitor INK1316 generally had greater effects on NK cell functions than the single inhibitors. Together with the results using IC87114 and the pan-PI3K inhibitors, these data support the conclusion that multiple class I PI3K isoforms (p110\(\alpha\), p110\(\beta\) and p110\(\delta\)) all provide overlapping contributions to NK cell function in response to activating ligands or missing self.

The anti-cancer activity of compounds targeting PI3K enzymes will depend not only on direct effects on tumor cells but also on indirect modulation of immune cells. The immune effects of PI3K inhibitors will also influence the efficacy of immunotherapies used in combination. The data presented here suggest that selective p110\(\alpha\) inhibition will preserve the function of NK cells, an important cell type in tumor immunosurveillance and immunotherapy.
Materials and Methods

Reagents

All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise noted. MLN1117 (MLN1117; p110α-selective inhibitor), A66 (p110α-selective inhibitor), and INK1316 (INK1316; dual p110α/β inhibitor) were obtained from Intellikine, Inc. (La Jolla, CA), now part of Millennium Pharmaceuticals. TGX-221 (p110β-selective inhibitor), AS-252424 (p110γ-selective inhibitor), IC87114 (p110δ-selective inhibitor), GDC-0941 (pan-class IA PI3K inhibitor), and ZSTK474 (pan-class IA PI3K inhibitor) were obtained from Chemdea (Ridgewood, NJ). AS-252424 was reconstituted in ethanol (EtOH) and the other inhibitors were reconstituted in DMSO. All aliquots were stored at −80°C and working solutions were prepared freshly, prior to the addition of inhibitors to cell cultures.

Mice

All of the animal protocols used were approved by the Institutional Animal Care and Use Committee at UC Irvine. Female C57BL/6 mice six weeks of age were purchased from The Jackson Laboratory. On arrival, the mice were randomized, transferred to plastic cages containing sawdust bedding (5 mice per cage), and quarantined for 1 week. The mice were given food (Purina Certified Laboratory Chow) and water ad libitum. Animal holding rooms were kept at 21°C to 24°C and 40% to 60% relative humidity with a 12-h light/dark cycle.

Cell lines

RMA, RMA-S, ELA, ELA-HSF and YAC-1 cells were described previously [27]. CCRF-CEM, human acute T lymphocytic leukemia cell line was kindly provided by Dr. Matthew Janes (Intellikine, La Jolla, CA). The human NK cell line NKL was provided by Dr. Melissa Lodoen (UC Irvine). K562 cells were obtained from Dr. Tiong Ong (Duke-National University of Singapore). NK92 cells were from ATCC (Manassas, VA). All cells were cultured in RPMI1640 medium supplemented with 10% FBS, 100 U/ml penicillin-streptomycin, 2 mM L-glutamine, 5 mM HEPES buffer, and 50 mM 2-mercaptoethanol, which we refer to as complete RPMI. For NKL and NK92 cells, the media was supplemented with human IL-2 (300 U/ml).

Human NK cell isolation

Peripheral blood mononuclear cells (PBMCs) were isolated from 25–30 ml of human buffy coat obtained from the donor center at the BloodCenter of Wisconsin, using Ficoll-Paque Plus (17-1440-02, GE Healthcare, Uppsala, Sweden). NK cells were isolated from 200–300 million PBMCs, using EasySep Negative Selection Human NK Cell Enrichment Kit (19055, Stemcell technologies, Vancouver, Canada).
Cell purification and NK cell expansion

Spleens were aseptically isolated from the mice, and NK cells were purified by negative selection using the NK-cell isolation kit (Miltenyi Biotec, Auburn, CA). Negative magnetic selection was also used to purify T cells from lymph node, and B cells from spleens. Purified NK cells were expanded for 7–8 days in complete RPMI with 1000 U/ml recombinant human interleukin-2 (IL-2) (Frederick National Laboratory for Cancer Research, Frederick, MD). Purity of the NK cultures was determined by flow cytometry.

Flow cytometry

Anti-mouse NK1.1 (PK136), CD3e (145-2C11), IFN-γ (XMG1.2), NKG2D (A10), NKG2A/C/E (20d5), CD49b (DX5), CD122 (5H4), CD11b (M1/70), and CD27 (LG.7F9) were obtained from eBioscience. mAbs for Ly49A (A1), Ly49D (4E5), Ly49C/I (5E6), and Ly49G2 (4D11) were obtained from BD Biosciences. The antibodies were conjugated to fluorescein isothiocyanate, pacific blue, phycoerythrin, allophycocyanin, or peridinin chlorophyll protein. A standard flow cytometry analysis was performed using a FACS Calibur (BD Bioscience) with FlowJo software (TreeStar, Ashland, OR).

Cytotoxicity assay

NK cell mediated cytotoxicity (CMC) and antibody-dependent cellular cytotoxicity (ADCC) were measured by calcein-AM release assay, with sensitivity similar to traditional 51Cr release assay (Roden et al., J Immunol Methods 1999; Neri et al., Clin Diagn Lab Immunol 2001; Tai et al., Cancer Res 2005). A total of 5 × 10^3 target cells/well were mixed with NK effector cells at indicated E:T ratios in pentaplicates and incubated for 2–4 hours at 37°C in IL-2-free medium in round-bottomed 96-well plates. Target cells including RMA, RMA-S, EL4, EL4<sup>H60</sup>, YAC-1, CCRF-CEM and K562 cells were labeled with 10 μM calcein-AM (Molecular Probes, Eugene, OR), washed, and used for co-culture with NK cells. Indicated concentrations of PI3K inhibitors or AKT inhibitor were added to NK cells for 15 minutes at 37°C prior to co-culture with target cells. DMSO was used as vehicle.
control in the media and ethanol was used as vehicle control for AS252424. For ADCC, 2 μg/ml mouse anti-human CD4 mAb was added. After 2–4 hour co-culture, 100 μl culture supernatants were transferred to a 96-well black plate (Nunc) and arbitrary fluorescent units (AFU) were read on Molecular Devices Spectra MAX GeminiXS (405 nm excitation/530 nm emission). Calculation of percentage of specific lysis from pentaplicate experiments was done using the following equation: % specific lysis = ([AFU mean experimental release - AFU mean spontaneous release]/(AFU mean maximal release - AFU mean spontaneous release)) x 100, where “AFU mean spontaneous release” is calcine release by target cells in the absence of NK cells and “AFU mean maximal release” is calcine release by target cells upon lysis by 2% Triton X-100. Cytotoxicity assays for NK92 or primary human NK cells were done with K562 cells as targets using a 51Cr release assay, as described [46].

Cytokine and chemokine quantification

NK cells (5 x 10⁴ cells/well) were incubated for 15 min at 37°C in the absence or in the presence of PI3K inhibitors prior to stimulation. The cells were stimulated with 5 μg/ml of plate-bound anti-NK2G2D (A10) or anti-NK1.1 (PK136) mAbs for indicated time periods. IFN-γ was measured by intracellular staining, ELISA, multiplexing assay, and RT-PCR. Other cytokines and chemokines were quantified by multiplexing assay. For intracellular staining, NK cells were stimulated with anti-NKG2D or anti-NK1.1 mAbs for 18 h in the presence of Brefeldin A for the last 4 h of activation. Where indicated in the figures, NK cells were activated with 10 ng/ml IL-12 and 1 ng/ml IL-18 in the presence of anti-NKG2D mAb (A10). Activated NK cells were Fc-blocked; stained for NK1.1 and CD3ε mAbs; fixed in 2% paraformaldehyde; permeabilized using 0.5% saponin; and quantified for intracellular IFN-γ using APC-conjugated anti-IFN-γ mAbs (eBioscience) through flow cytometry. The primary gate was drawn on the total population of viable cells and then gated based on surface NK1.1 and CD3ε expression. Intracellular IFN-γ levels were determined from the NK1.1+/CD3ε− population. To determine the secreted cytokines and chemokines, NK cells were stimulated with anti-NKG2D mAbs in the absence or presence of PI3K inhibitors for 18 h and the supernatant was collected. IFN-γ was quantified using ELISA and multiplexing assay. Other cytokines and chemokines including IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12, IL-12 (p40), IL-12 (p70), Eotaxin, G-CSF, GM-CSF, MCP-1, MIP-1α (CCL3), MIP-1β (CCL4), RANTES (CCL5), and TNF-α were quantified using Multiplex kit (Bio-Rad Laboratories). Sandwich ELISA for IFN-γ was performed with a Ready-set-go kit from eBioscience, and intracellular IFN-γ was measured by intracellular staining, ELISA, multiplexing assay, and RT-PCR. Other cytokines and chemokines from C57BL/6 mice along with the SKOV and U87MG cell lines (ATCC, Manassas, VA) were lysed and 30 μg protein were separated by SDS-PAGE. Proteins were transferred to nitrocellulose and probed with the following antibodies to the different PI3K isoforms: p110α (C73F8), p110β (D55D5), p110γ (D55D5) (Cell Signaling Technology) and the bands were visualized using the ECL system (Amersham Biosciences). For measurement of p110 isoform expression, purified B, T and NK cells from C57BL/6 mice were activated with 10 ng/ml IL-12 and 1 ng/ml IL-18 in the presence of anti-NKG2D mAbs for indicated time periods. IFN-γ was measured by intracellular staining, ELISA, multiplexing assay, and RT-PCR. Other cytokines and chemokines from C57BL/6 mice along with the SKOV and U87MG cell lines (ATCC, Manassas, VA) were lysed and 30 μg protein were separated by SDS-PAGE. Proteins were transferred to nitrocellulose and probed with the following antibodies to the different PI3K isoforms: p110α (C75F0), p110β (C33D4), p110γ (D55D5) (Cell Signaling Technology), p110δ (Abcam, Cambridge, MA) and Actin (Sigma Aldrich).

In vivo NK cell development

Wild-type C57BL/6 mice were orally dosed either with vehicle, MLN1117, or GDC-0941 using a sterile disposable 20G-1.5" feeding needle (Fisher). Four mice per group were given the indicated drugs for 7 d before sacrificing on day 8. Spleen and bone marrow (BM) were isolated and analyzed for NK cell development by flow cytometry. In all cases, the vehicle group received both vehicles used to formulate the two different drugs.

Statistical analysis

The means ± standard errors of the means (SEM) were determined for each treatment group in the individual experiments and/or three independent experiments. Statistical analysis was performed with the unpaired Student’s t test or one-way ANOVA, with each condition compared to the stimulated-vehicle control. Each inhibitor except for AS-252424 was compared to DMSO vehicle; AS-252424 was compared to ethanol vehicle.

Supporting Information

Figure S1 Representative NK cell purity. NK cells from C57BL/6 mice were purified from spleen and expanded for 7 days in IL-2. Purities of the NK cells from freshly isolated cells and 7 day-cultured cells were measured in CD1−NK1.1+ NK cells by surface staining and FACS.

Figure S2 Pan-PI3K inhibition suppresses NK cell-mediated cytotoxicity. NK cells from C57BL/6 mice were purified from spleen and expanded for 7–8 days in IL-2. Cytotoxicity was determined by calcine release assay with the NK cells and calcine AM-labeled target cells at the indicated
**Figure S5** Isoform-selective inhibitors have little effect on cytotoxicity of human NK92 cells. K562 cells were labeled with $^{51}$Cr and co-cultured with human NK92 cells at the indicated E:T ratios in the presence of 1 μM indicated inhibitors (TGX-221, GDC-0941, and ZSTK474 were 0.5 μM) for 2 h. Specific $^{51}$Cr release was measured as in Figure 3A. The data are expressed as the average of two independent experiments. (TIF)

**Figure S5** Representative FACS plots showing IFN-γ production in anti-NKG2D-stimulated NK cells. The NK cells were stimulated with plate-bound anti-NKG2D mAb in the presence of 1 μM indicated inhibitors (TGX-221 was 0.5 μM). After 18 h stimulation, the NK cells were harvested and the intracellular IFN-γ level was determined by flow cytometry. Brefeldin A was added for the last 4 h before cell harvest and IFN-γ production was measured in CD3−NK1.1+ NK cells by intracellular staining. The results presented are representative of three independent experiments. (TIF)

**Acknowledgments**

We thank Melissa Lodoen for advice on NK cell culture and functional assays, and Matthew Janes for helpful suggestions. We are indebted to Christian Rommel, Yi Liu and their colleagues at Intellikine for initial support of this project.

**Author Contributions**

Conceived and designed the experiments: SSY LS JL KR S. Malarkan DAF. Performed the experiments: SSY LS S. Mallya JL KR. Analyzed the data: SSY LS S. Mallya JL KR S. Malarkan DAF. Wrote the paper: SSY LS S. Mallya JL KR S. Malarkan DAF.

**References**

1. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29: 235–271.
2. Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12: 237–251.
3. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G (2013) Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39: 74–88.
4. Fruman DA, Rommel C (2011) PI3Kdelta Inhibitors in Cancer: Rationale and preclinical data. Cancer Lett 318: 172–185.
5. Liu P, Cheng H, Roberts TM, Zhao J (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627–644.
6. Workman P, Clarke PA, Raynaud FI, van Montfort RL (2010) Drugging the PI3 kinase pathway. Nat Rev Drug Discov 9: 109–127.
7. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
8. Furet P, Giagnazano V, Fairhurst RA, Inhach-Wesse P, Bruce I, et al. (2013) Discovery of NVP-BYL719: a potent and selective phosphatidylinositol-3-kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett 23: 3741–3748.
9. Jesen K, Kessler L, Kiechardt J, Guo X, Staunton J, et al. (2011) A potent and selective PI3K alpha inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations. Mol Cancer Ther 10: Abstract A171.
10. So L, Yea SS, Ouk JS, Lu M, Manmadhan A, et al. (2013) Selective inhibition of phosphoinositol-3-kinase p110alpha preserves lymphocyte function. J Biol Chem 288: 5718–5731.
11. Puri KD, Gold MR (2012) Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front Immunol 3: 256.
12. Dibouk HA, Vadas O, Shyamantas A, Burke JL, Salomon RS, et al. (2012) G Protein-Coupled Receptor-Mediated Activation of p110beta by Gbetagamma is Required for Cellular Transformation and Invasiveness. Sci Signal 5: ra89.
13. Schmid MC, Avraamides CJ, Dippold HG, Franco I, Foubert P, et al. (2011) Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3Kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19: 715–727.
14. Schmid MC, Avraamides CJ, Dippold HG, Franco I, Foubert P, et al. (2011) PI3Kdelta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Blood 110: 3202–3208.
15. Vivier E, Raulot DH, Moretta A, Calugiari MA, Zitvogel L, et al. (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331: 44–49.
16. Vivier E, Tomaselli E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9: 503–510.
17. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L (2012) Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12: 239–252.
18. Kim JM, Ashkenazi A (2013) Fcgamma receptors enable antitumor action of prophagotic and immune-modulatory antibodies. J Exp Med 210: 1647–1651.
19. Scott AM, Wedokh JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12: 278–287.
20. Aoukaty A, Tan R (2002) Association of the X-linked lymphoproliferative disease gene product SAP/SH2D1A with 2B4, a natural killer cell-activating molecule, is dependent on phosphoinositol-3-kinase. J Biol Chem 277: 13331–13337.
21. Bonnema JD, Karnitz LM, Schoon RA, Abraham RT, Leahson PJ (1994) Fc receptor stimulation of phosphatidylinositol 3-kinase in natural killer cells is associated with protein kinase C-dependent granule release and cell-mediated cytotoxicity. J Exp Med 180: 1427–1435.
22. Jiang K, Zhong B, Gilvary DL, Corliss BC, Hong-Geller E, et al. (2000) Pivotal role of phosphatidylinositol-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol 1: 419–426.
23. Kanakaraj P, Duckworth R, Azzoni L, Kamoun M, Canley LG, et al. (1994) Phosphatidylinositol-3 kinase activation induced upon Fc gamma RIIA ligand interaction. J Exp Med 179: 531–538.
24. Kim N, Sautenmont A, Webb L, Camps M, Rucile T, et al. (2007) The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Blood 110: 3202–3208.
25. Fougas LC, Claret M, Pearce W, Okedenhaug K, Merck S, et al. (2006) Critical role for the p110alpha phosphatidylinositol-3-OH kinase in growth and metabolic regulation. Nature 441: 366–370.
26. Awhali A, Samarakoon A, Dai X, Wen R, Wang D, et al. (2008) Deletion of PI3K-p110alpha gene impairs lineage commitment, terminal maturation, cytokine generation and cytotoxicity of NK cells. Genes Immun 9: 522–533.
27. Guo H, Samarakoon A, Vanhaesebroeck B, Malarkan DAF (2008) The p110delta of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation. J Exp Med 205: 2419–2435.
28. Sautenmont A, Garcon F, Yadi H, Roche-Molina M, Kim N, et al. (2009) p110gamma and p110delta isoforms of phosphoinositol 3-kinase differentially
29. Tassi I, Cella M, Gillilan S, Turnbull I, Diacono T, et al. (2007) p110gamma and p110delta phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells. Immunology 27: 214–227.
30. Zebedin E, Simma O, Schuster C, Putz EM, Fajmann S, et al. (2008) Leukemic challenge unmask a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood 112: 4655–4664.
31. Kong D, Yamori T (2007) ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci 98: 1638–1642.
32. Rewcastle GW, Gamage SA, Flanagan JU, Frederick R, Denny WA, et al. (2011) Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). J Med Chem 54: 7105–7126.
33. Edgar KA, Wallin JJ, Berry M, Lee LB, Prior WW, et al. (2010) Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Res 70: 1164–1172.
34. Folkes AJ, Ahmadi K, Alderton WK, Alik S, Baker SJ, et al. (2008) The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl)piperazin-1-yl)methyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 51: 5522–5528.
35. Raynaud FI, Eccles SA, Patel S, Alik S, Box G, et al. (2009) Biological properties of potent inhibitors of class I phosphatidylinositol 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 8: 1725–1738.
36. Jamieson S, Flanagan JU, Kolekar S, Buchanan C, Kendall JD, et al. (2011) A drug targeting only p110alpha can block phosphoinositol 3-kinase signalling and tumour growth in certain cell types. Biochem J 438: 53–62.
37. Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Cho K, et al. (2007) Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J 404: 449–458.
38. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbit WS, Yap CL, et al. (2005) PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 11: 507–514.
39. Bilancio A, Okkenhaug K, Camps M, Emery JL, Rockle T, et al. (2006) Key role of the p110delta isoform of PI3K in B-cell antigen and B-A receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 107: 642–650.
40. Sound DR, Bjorge E, Moltu K, Dale VQ, Patton DT, et al. (2010) PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 115: 2203–2213.
41. Scharton TM, Scott P (1993) Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 170: 567–577.
42. Summers V, Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18: 77–82.
43. Putz EM, Prchal-Murphy M, Simma OA, Forster F, Koernig X, et al. (2012) PI3Kdelta is essential for tumor clearance mediated by cytotoxic T lymphocytes. PLoS One 7: e40852.
44. Fritsch R, de Krijger I, Fritsch K, George R, Reason B, et al. (2013) RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms. Cell 153: 1050–1063.
45. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11: 329–341.
46. Regunathan J, Chen Y, Wang D, Malarkannan S (2005) NK2D1 receptor-mediated NK cell function is regulated by inhibitory Ly49 receptors. Blood 105: 233–240.